stars 1 stars 2 stars 3

The first tissue regeneration therapy for Short Bowel Syndrome (SBS). SBS is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. It results from the surgical removal of a large portion of the small intestine due to a congenital or acquired defect. The Eclipse XL1 therapy is designed to grow 2-3x longer, healthy intestine within 2-3 weeks using an entirely mechanical, repeatable approach. The new tissue has been shown to absorb nutrients and function the same as, or better than, healthy intestinal tissue. The Eclipse XL 1 device is an investigational product and limited by Federal law to investigational use. It is not currently available for commercial sale in the U.S. or any other region. Eclipse Regenesis and Eclipse XL1 are registered trademarks of Eclipse Regenesis, Inc.

Eclipse Regenesis Questions

Andre Bessette is the CEO of Eclipse Regenesis.

4 people are employed at Eclipse Regenesis.

Eclipse Regenesis is based in Menlo Park, California.

Top Eclipse Regenesis Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users